Which drug used for the treatment of asthma inhibits 5-lipoxygenase?

Which drug used for the treatment of asthma inhibits 5-lipoxygenase?

Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma.

What effect does a cyclooxygenase inhibitor have on eicosanoids?

B Biosynthesis and Actions of Eicosanoids Drugs such as aspirin and indomethacin inhibit cyclooxygenase and block the synthesis of prostaglandins and thromboxanes. Certain flavenoids obtained from plants also block cyclooxygenase. A separate enzyme, 5-lipoxygenase, forms the leucotrienes from arachidonic acid.

What is the mechanism of action of zileuton?

Mechanism of Action Zileuton is a 5-lipoxygenase inhibitor, which in turn, inhibits the formation of leukotrienes B4, C4, D4, E4. Limiting these leukotrienes, in turn, helps to reduce inflammation, edema, mucus secretion, and bronchoconstriction in the airways.

Is Montelukast a lipoxygenase inhibitor?

Here we report that montelukast, a structural Cys-LT1 receptor antagonist, also exerts a substantial and apparently direct inhibitory effect on 5-lipoxygenase activity in vitro, at concentrations in the lower micromolar range, which are of potential therapeutic relevance.

Which of the following drugs is a 5-lipoxygenase 5 LOX inhibitor?

Zileuton, a selective 5-LOX inhibitor, has antiinflammatory properties and exerts an inhibitory effect on inflammatory diseases.

What is cyclooxygenase and lipoxygenase?

Cyclooxygenase- and lipoxygenase-catalyzed arachidonic. acid metabolism. Two major metabolic routes, i.e., the COX and LOX pathways, control the biosynthesis of eicosanoids.

What are lipoxygenase products?

Major products: it metabolizes arachidonic acid to 5-hydroperoxy-eicostetraeoic acid (5-HpETE) which is converted to 1) 5-Hydroxyicosatetraenoic acid (5-HETE) and then to 5-oxo-eicosatetraenoic acid (5-oxo-ETE), 2) leukotriene A4 (LTA4) which may then be converted to leukotriene B4 (LTB4) or Leukotriene C4 (LTC4) (LTC4 …

Is montelukast a leukotriene receptor antagonist?

Montelukast is a potent, specific antagonist of leukotriene receptors10,11 that was recently approved in the United States and other countries for the treatment of chronic asthma. The protective effects of two doses of montelukast on exercise-induced bronchoconstriction have been shown at 20 to 24 hours after dosing.